July 14, 2009
Milford Firm Takes Aim At Cystic Fibrosis Testing
By Matthew L. Brown
Milford-based SeraCare Life Sciences Inc. has launched a new line of products designed to aid genetic research in cystic fibrosis.
The products are genetic controls and the company said they are the only controls that can be used to test all cystic fibrosis mutations detected by leading testing platforms. A control is used in scientific testing to challenge the accuracy of and detect errors in testing.
Cystic fibrosis is typically diagnosed in children before the age of 2. In order to be infected, a child must inherit two copies of the defective cystic fibrosis gene, one from each parent. About 1 in 31 Americans is a carrier for the disease.
WBJ Web Partners
Most Recent
Most Recent
0 Comments